XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.2

Commitments and Contingencies - Additional Information (Detail) shares in Millions	1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended
	Aug. 31, 2020 USD ($) shares	Mar. 31, 2020 USD ($)	Aug. 31, 2018 USD ($)	Sep. 30, 2020 USD ($)	Mar. 31, 2020 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2018 USD ($)	Jun. 21, 2021 Motion	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Other Commitments [Line Items]
Obligation expiration year						2021
Gain (loss) on strategic investment						$ 323,000	$ (1,060,000)
Restricted cash						5,770,000	$ 5,770,000			$ 5,770,000	$ 4,787,000
Number Of Motions | Motion									5
Letter of Credit | Corporate Credit Card Program
Other Commitments [Line Items]
Restricted cash						2,000,000.0
Letter of Credit | Fleet Program
Other Commitments [Line Items]
Restricted cash						400,000
Cersci Therapeutics
Other Commitments [Line Items]
Upfront consideration and transaction costs	$ 52,800,000
Upfront payment	$ 44,300,000
Upfront payment conditions	The Company incurred an aggregate of $52.8 million in upfront consideration and transaction costs, of which, $44.3 million was paid through the issuance of approximately 1.2 million shares of the Company’s common stock.
Common stock issuance | shares	1.2
Cersci Therapeutics | Research and development
Other Commitments [Line Items]
Assets acquisition and upfront payment				$ 45,700,000
License Agreements
Other Commitments [Line Items]
Upfront payment						$ 5,000,000.0
License Agreements | Neuren | North America
Other Commitments [Line Items]
Upfront payment		$ 10,000,000.0
Upfront license fee			$ 10,000,000.0
License Agreements | Neuren | Research and development | North America
Other Commitments [Line Items]
Upfront payment					$ 10,000,000.0			$ 10,000,000.0
Maximum
Other Commitments [Line Items]
Percentage of royalty payments obligation on net product sales						2.00%
Mile stone payments payable						$ 2,200,000,000
Maximum | Cersci Therapeutics | Development Commercialization and Sales Milestones
Other Commitments [Line Items]
Compensation expense related to mergers to former holders	$ 887,000,000.0
Maximum | License Agreements | Neuren | North America
Other Commitments [Line Items]
Mile stone payments payable		$ 515,000,000.0	$ 455,000,000.0		$ 515,000,000.0

X

- Definition

Collaborative arrangements assets acquisition and upfront payment.

+ References

No definition available.

+ Details

Name:	acad_CollaborativeArrangementsAssetsAcquisitionAndUpfrontPayment
Namespace Prefix:	acad_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Collaborative arrangements non-cash upfront payment.

+ References

No definition available.

+ Details

Name:	acad_CollaborativeArrangementsNonCashUpfrontPayment
Namespace Prefix:	acad_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Collaborative Arrangements Upfront consideration and transaction Payment.

+ References

No definition available.

+ Details

Name:	acad_CollaborativeArrangementsUpfrontConsiderationAndTransactionPayment
Namespace Prefix:	acad_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Collaborative arrangements upfront license fee.

+ References

No definition available.

+ Details

Name:	acad_CollaborativeArrangementsUpfrontLicenseFee
Namespace Prefix:	acad_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Collaborative arrangements upfront payment.

+ References

No definition available.

+ Details

Name:	acad_CollaborativeArrangementsUpfrontPayment
Namespace Prefix:	acad_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Collaborative Arrangements Upfront payment description.

+ References

No definition available.

+ Details

Name:	acad_CollaborativeArrangementsUpfrontPaymentDescription
Namespace Prefix:	acad_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaborative arrangements upfront payment shares issued.

+ References

No definition available.

+ Details

Name:	acad_CollaborativeArrangementsUpfrontPaymentSharesIssued
Namespace Prefix:	acad_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Compensation expense related to mergers to former holders.

+ References

No definition available.

+ Details

Name:	acad_CompensationExpenseRelatedToMergersToFormerHolders
Namespace Prefix:	acad_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Number of motions for lead plantiff and lead counsel.

+ References

No definition available.

+ Details

Name:	acad_NumberOfMotions
Namespace Prefix:	acad_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Obligation expiration year.

+ References

No definition available.

+ Details

Name:	acad_ObligationExpirationYear
Namespace Prefix:	acad_
Data Type:	xbrli:gYearItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Payment of royalty percentage on net product sales.

+ References

No definition available.

+ Details

Name:	acad_PaymentOfRoyaltyPercentageOnNetProductSales
Namespace Prefix:	acad_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.

+ References

No definition available.

+ Details

Name:	us-gaap_ContractualObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of realized and unrealized gain (loss) on investment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121645371&loc=d3e27405-111563

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(c),9(a))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

+ Details

Name:	us-gaap_GainLossOnInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitmentsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 210
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580

+ Details

Name:	us-gaap_RestrictedCashNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Details

Name:	us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_OtherCommitmentsAxis=acad_CorporateCreditCardProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_OtherCommitmentsAxis=acad_FleetProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=acad_CersciTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=acad_LicenseAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=acad_NeurenPharmaceuticalsLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=srt_NorthAmericaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_IncomeStatementLocationAxis=acad_DevelopmentCommercializationAndSalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: